CPI-17 (phospho-T38) polyclonal, anti-human, mouse, rat
€328.00
In stock
SKU
BS4780
Background:
CPI-17 is a phosphorylation-dependent inhibitory protein for smooth muscle myosin phosphate. CPI-17 was originally identified as a PKC-potentiated inhibitory protein of protein phosphatase-1, which is dominantly expressed in smooth muscle. Phosphorylation at Threonine 38, in vitro, by PKC or Rho-kinase enhances the inhibitory potency toward myosin phosphatase. CPI-17 is also phosphorylated at Threonine 38 by protein kinase N and might be involved in the calcium sensitization of smooth muscle contraction as a downstream effector of Rho and/or arachidonic acid. CPI-17 is dually phosphorylated at Serine 12 and Threonine 38 by a MYPT-associated kinase, M110 kinase.
Alternative Name:
Protein phosphatase 1 regulatory subunit 14A, 17 kDa PKC-potentiated inhibitory protein of PP1, Protein kinase C-potentiated inhibitor protein of 17 kDa, CPI-17, CPI17, PPP1INL, PPP1R14A
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200
Specificity: p-CPI-17 (T38) polyclonal antibody detects endogenous levels of CPI-17 polyclonal antibody protein only when phosphorylated at Thr38.
Immunogen:
Synthetic phosphopeptide derived from human CPI-17 around the phosphorylation site of Threonine 38.
MW: ~ 22 kDa
Swis Prot.: Q96A00
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
CPI-17 is a phosphorylation-dependent inhibitory protein for smooth muscle myosin phosphate. CPI-17 was originally identified as a PKC-potentiated inhibitory protein of protein phosphatase-1, which is dominantly expressed in smooth muscle. Phosphorylation at Threonine 38, in vitro, by PKC or Rho-kinase enhances the inhibitory potency toward myosin phosphatase. CPI-17 is also phosphorylated at Threonine 38 by protein kinase N and might be involved in the calcium sensitization of smooth muscle contraction as a downstream effector of Rho and/or arachidonic acid. CPI-17 is dually phosphorylated at Serine 12 and Threonine 38 by a MYPT-associated kinase, M110 kinase.
Alternative Name:
Protein phosphatase 1 regulatory subunit 14A, 17 kDa PKC-potentiated inhibitory protein of PP1, Protein kinase C-potentiated inhibitor protein of 17 kDa, CPI-17, CPI17, PPP1INL, PPP1R14A
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200
Specificity: p-CPI-17 (T38) polyclonal antibody detects endogenous levels of CPI-17 polyclonal antibody protein only when phosphorylated at Thr38.
Immunogen:
Synthetic phosphopeptide derived from human CPI-17 around the phosphorylation site of Threonine 38.
MW: ~ 22 kDa
Swis Prot.: Q96A00
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review